MedTrace Logo

Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

NCT06555133 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-04-09

No results posted yet for this study

Summary

BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.

Conditions

  • Colorectal Carcinoma Metastatic in the Liver

Interventions

COMBINATION_PRODUCT

yttrium-90 radioembolization

yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.

Sponsors & Collaborators

  • Sirtex Medical

    collaborator INDUSTRY

  • Genentech, Inc.

    collaborator INDUSTRY

  • Brown University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-07
Primary Completion
2026-09-01
Completion
2029-09-01
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06555133 on ClinicalTrials.gov